Oligodendrocyte Progenitor Cell Isolation via Sequential Marker Selection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods fail to isolate relatively pure populations of oligodendrocyte progenitor cells from mixed neural cell populations, especially for high yields needed in cellular transplants for myelin-related disorders, as existing markers like A2B5 do not effectively eliminate neuronal and astrocytic contaminants.

Innovation Solution

The use of oligodendrocyte-biased glial progenitor cells selected by markers such as PDGFαR and CD9, combined with the absence of PSA-NCAM and CD11, to isolate a substantially pure population of oligodendrocyte-biased glial progenitor cells, which can be immortalized and used for transplantation and screening agents modulating glial cell fate.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If existing markers like A2B5 are used to isolate oligodendrocyte progenitor cells, then cell isolation can be performed, but neuronal and astrocytic contaminants cannot be effectively eliminated

Engineering Contradiction:

Improvepurity of isolated oligodendrocyte progenitor cellsVSAvoidcomplexity of marker selection process

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent segments the cell isolation process into multiple sequential steps using different marker combinations. First, A2B5+ cells are selected from the neural cell population, then PSA-NCAM- selection is applied to remove neuronal contaminants, and finally CD11- selection removes microglial contaminants. This multi-stage segmentation approach achieves high purity oligodendrocyte progenitor cell populations that cannot be obtained with single markers alone.

Inventive Principle:

Principle #1Segmentation

2Manufacturing precision

If multiple selection steps are used to improve cell purity, then contaminant elimination is enhanced, but the isolation process becomes more complex

Engineering Contradiction:

Improvepurity of isolated oligodendrocyte progenitor cellsVSAvoidsimplicity of isolation procedure

Core Design Contradiction:

Manufacturing precisionVSEase of operation

Solution Approach 1:

The patent develops universal marker combinations that can be applied across different neural cell sources (fetal brain, stem cell derivatives, adult neural tissue) to consistently isolate oligodendrocyte progenitor cells with high purity. The A2B5+/PSA-NCAM-/CD11- marker profile serves as a universal selection criterion that works across multiple starting materials and experimental conditions, simplifying the overall process despite the multiple selection steps required.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Productivity

If high yields of pure oligodendrocyte progenitor cells are needed for transplantation, then cell expansion is required, but maintaining purity during expansion becomes difficult

Engineering Contradiction:

Improveyield of oligodendrocyte progenitor cellsVSAvoidpurity of expanded cell population

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent applies preliminary selection using the A2B5+/PSA-NCAM-/CD11- marker profile to isolate a highly pure oligodendrocyte progenitor cell population before expansion. By establishing the correct cell phenotype upfront through rigorous marker-based selection, the subsequent in vitro expansion maintains purity because the selected cells are already committed to the oligodendrocyte lineage and do not differentiate into contaminant cell types during culture.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12178834B2Treating myelin diseases with optimized cell preparations

Publication Date: 2024.12.31 UNIVERSITY OF ROCHESTER

AI summary

The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.